LU90710I2 - Galanthamine ou ses sels d'addition acides - Google Patents

Galanthamine ou ses sels d'addition acides

Info

Publication number
LU90710I2
LU90710I2 LU90710C LU90710C LU90710I2 LU 90710 I2 LU90710 I2 LU 90710I2 LU 90710 C LU90710 C LU 90710C LU 90710 C LU90710 C LU 90710C LU 90710 I2 LU90710 I2 LU 90710I2
Authority
LU
Luxembourg
Prior art keywords
galanthamine
acid addition
addition salts
alzheimer
disease
Prior art date
Application number
LU90710C
Other languages
English (en)
French (fr)
Original Assignee
Synaptech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25227312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90710(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synaptech Inc filed Critical Synaptech Inc
Publication of LU90710I2 publication Critical patent/LU90710I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
LU90710C 1986-01-15 2001-01-03 Galanthamine ou ses sels d'addition acides LU90710I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/819,141 US4663318A (en) 1986-01-15 1986-01-15 Method of treating Alzheimer's disease

Publications (1)

Publication Number Publication Date
LU90710I2 true LU90710I2 (fr) 2001-03-05

Family

ID=25227312

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90710C LU90710I2 (fr) 1986-01-15 2001-01-03 Galanthamine ou ses sels d'addition acides

Country Status (10)

Country Link
US (1) US4663318A (forum.php)
EP (1) EP0236684B1 (forum.php)
JP (1) JPH08778B2 (forum.php)
AT (1) ATE76294T1 (forum.php)
AU (1) AU593051B2 (forum.php)
DE (3) DE10199020I2 (forum.php)
ES (1) ES2000428T3 (forum.php)
GR (2) GR880300077T1 (forum.php)
LU (1) LU90710I2 (forum.php)
NL (1) NL300140I2 (forum.php)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0363415B1 (en) * 1987-05-04 2008-10-15 Davis, Bonnie Compounds for the treatment of alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
IT1222395B (it) * 1987-07-30 1990-09-05 Pierrel Spa Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
EP0515301A3 (en) * 1991-05-14 1993-06-16 Ernir Snorrason Improvements in benzodiazepine treatment by cholinesterterase inhibitors
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) * 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
PL184590B1 (pl) * 1994-10-21 2002-11-29 Sanochemia Pharmazeutika Ag Sposób wytwarzania pochodnych a heksahydro H benzofuro[ a ef][ ] benzoazepiny sposób odbromowania tych pochodnych sposób wytwarzania związków typu N demetylobromo i epibromo galantaminy oraz nowe związki z określonego zbioru
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU2004242546B2 (en) * 1998-11-23 2008-05-15 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
EP1133230A4 (en) * 1998-11-23 2004-05-26 Bonnie M Davis DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS
SK287676B6 (sk) * 1998-12-24 2011-05-06 Janssen Pharmaceutica N. V. Prostriedok s riadeným uvoľňovaním obsahujúci galantamín, spôsob jeho prípravy, dávková forma a farmaceutické balenie s jeho obsahom a použitie galantamínu na výrobu tohto prostriedku
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
ATE297737T1 (de) * 2000-01-28 2005-07-15 Tricia Grose Zusatz aus kräutern zur behandlung von kognitiven störungen aufgrund von östrogenverlust
US6426097B2 (en) 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss
MXPA01012275A (es) 2000-03-31 2003-06-24 Sanochemia Pharmazeutika Ag Derivados y analogos novedosos de galantamina.
CA2310990A1 (en) 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
KR100935615B1 (ko) 2002-06-14 2010-01-07 토야마 케미칼 컴퍼니 리미티드 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
CA2527114A1 (en) * 2003-05-30 2004-12-16 Microbia, Inc. Methods for the protection of memory and cognition
US20050048543A1 (en) * 2003-07-11 2005-03-03 Jeroen Aerssens CHRNA2 genetic markers associated with galantamine response
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
WO2005014002A1 (en) * 2003-07-25 2005-02-17 F. Hoffmann-La Roche Ag Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
US20050260613A1 (en) * 2003-10-28 2005-11-24 Genaissance Pharmaceuticals LRPAP1 genetic markers associated with galantamine
BG65658B1 (bg) * 2003-11-13 2009-05-29 "Софарма" Ад Комбиниран лекарствен продукт на основата на галантамин
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US7250258B2 (en) * 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
EP1718291A1 (en) * 2004-02-19 2006-11-08 Novartis AG Use of cholinesterase inhibitors for treating vascular depression
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
KR20070004036A (ko) * 2004-04-29 2007-01-05 키스톤 리테이닝 월 시스템스, 아이엔씨 벽, 옹벽 및 그 외 유사한 것을 위한 베니어
WO2005112908A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP1819681B1 (en) * 2004-11-23 2009-08-12 Warner-Lambert Company LLC 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006071274A2 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
WO2007014124A2 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2008051599A2 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
AU2009229372C1 (en) * 2008-03-27 2017-02-02 Chase Pharmaceuticals Corporation Use and composition for treating dementia
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
ES2746480T3 (es) 2009-09-18 2020-03-06 Chase Pharmaceuticals Corp Combinación para tratar demencia de tipo Alzheimer
WO2011064797A2 (en) 2009-11-26 2011-06-03 Usv Limited Controlled release pharmaceutical compositions of galantamine
CN109662964A (zh) 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
HK1210947A1 (en) 2012-09-05 2016-05-13 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
BG66818B1 (bg) 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2921308A1 (en) 2013-08-16 2015-02-19 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam

Also Published As

Publication number Publication date
JPS62215527A (ja) 1987-09-22
AU6760987A (en) 1987-07-16
EP0236684A2 (en) 1987-09-16
AU593051B2 (en) 1990-02-01
NL300140I2 (nl) 2004-04-01
DE10199020I1 (de) 2001-05-23
ATE76294T1 (de) 1992-06-15
DE3779149D1 (de) 1992-06-25
GR3005447T3 (forum.php) 1993-05-24
DE10199020I2 (de) 2004-05-06
EP0236684A3 (en) 1988-12-14
DE236684T1 (de) 1988-04-28
ES2000428T9 (es) 2013-08-14
GR880300077T1 (en) 1988-10-21
US4663318A (en) 1987-05-05
ES2000428T3 (es) 1993-10-01
ES2000428A4 (es) 1988-03-01
JPH08778B2 (ja) 1996-01-10
NL300140I1 (nl) 2004-02-02
EP0236684B1 (en) 1992-05-20

Similar Documents

Publication Publication Date Title
LU90710I2 (fr) Galanthamine ou ses sels d&#39;addition acides
DK549189D0 (da) Galanthamin-analoge samt anvendelse af disse til fremstilling af laegemidler til behandling af alzheimer&#39;s syge
DE3783068D1 (de) Medizinische vorrichtung.
DE19675046I2 (de) Pharmazeutische Verbindungen
DE68916693D1 (de) Molekular-Diagnose von Alzheimer-Krankheit.
DE3780618D1 (de) Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses.
ATA19687A (de) Magnetischer wasseraufbereiter
EP0268640A4 (en) Vaccine for stimulating or enhancing production of antibodies directed against gm2.
IT1217352B (it) Palizzata in calcestruzzo nonche&#39;procedimento e dispositivo per laproduzione della stessa.
BE892069A (fr) Le 3&#39;, 4&#39;, 5&#39;-trimethoxybenzoate de 17,18-deshydroapovincaminol et ses sels formes par addition avec des acides
FR2603284B1 (fr) Derives d&#39;acide 7-oxabicyclo(2.2.1.)heptane hydroxamique a action therapeutique
NO166225C (no) Fluorborsyresalt av n-tridecyl-2,6-dimetylmorfolin, fungicid og trebeskyttelsesmiddel inneholdende dette, samt anvendelse derav.
FR2583419B1 (fr) Procede pour la preparation de 2-bromo-a-ergocryptine et ses sels d&#39;addition d&#39;acides.
IT1192097B (it) Dispositivo per l&#39;introduzione delle pelli in macchine per conceria
IT8763326V0 (it) Presidio medico per l&#39;elettromagnetoterapia.
FI871737A0 (fi) Kraftanlaeggning med foerbraenning i en fluidiserad baedd.
IT8619228A0 (it) Procedimento di trattamento dell&#39;acqua.
IT8722869V0 (it) Dispositivo perfezionato per l&#39;abbronzatura artificiale integrale o parziale.
FI882581L (fi) Vattenbehaollare.
FI874099L (fi) Vattenrenare.
ES1003780Y (es) Plantilla de curvas senoidales biorritmicas.
FI893062L (fi) Vattenbehandlingsfoerfarande.
IT1216416B (it) Dispositivo per la sformatura di pali.
ATE101487T1 (de) Selbsttaetige tierbehandlung.
FI873352A7 (fi) Jätevesien biologinen käsittelytapa.